sulfonylureas


Also found in: Dictionary, Thesaurus, Wikipedia.
Related to sulfonylureas: Thiazolidinediones

sul·fo·nyl·u·re·as

(sŭl'fō-nil-yū-rē'ăz),
Derivatives of isopropylthiodiazylsulfanilamide, chemically related to the sulfonamides, which possess hypoglycemic action. Belonging to this series are acetohexamide, azepinamide, chlorpropamide, fluphenmepramide, glymidine, hydroxyhexamide, heptolamide, indylamide, thiohexamide, tolazamide, and tolbutamide.

sul·fo·nyl·u·re·as

(sŭl'fō-nil-yūr'ē-ăz)
Derivatives of isopropylthiodiazylsulfanilamide, chemically related to the sulfonamides, which possess hypoglycemic action. Belonging to this series are acetohexamide, azepinamide, chlorpropamide, fluphenmepramide, glymidine, hydroxyhexamide, heptolamide, indylamide, thiohexamide, tolazamide, and tolbutamide.
Synonym(s): sulphonylureas.

sul·fo·nyl·u·re·as

(sŭl'fō-nil-yūr'ē-ăz)
Derivatives of isopropylthiodiazylsulfanilamide, chemically related to sulfonamides, whichpossess hypoglycemic action (e.g., acetohexamide, tolbutamide).
Synonym(s): sulphonylureas.
References in periodicals archive ?
For sulfonylureas, that number was a bit higher -- 103 people.
Thyroid function in diabetic patients under long-term sulfonylurea treatment.
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Sulfonylureas, such as glimepiride, are widely used in human diabetic patients to stimulate insulin secretion from pancreatic beta cells and subsequently reduce hyperglycemia.
Options for add-on therapy include sulfonylureas, thiazolidines, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide 1 (GLP-1) agonists, and insulin.
Meglitinides should be avoided in patients with hypoglycemic unawareness or in patients who are unwilling/unable to check their blood glucose, despite the fact that these products are associated with less hypoglycemia then sulfonylureas.
Metformin as well as sulfonylureas were found to be more effective at reducing blood glucose levels than DPP-4 inhibitors.
On the basis of consistent findings from two randomized, controlled trials including 3,199 total participants (ADOPT and SPREAD-DIM-CAD), a lower risk for cardiovascular mortality was found for metformin monotherapy versus sulfonylurea monotherapy.
On the basis of consistent findings from two randomized, controlled trials including 3,199 total participants (ADOPT and SPREAD-DIMCAD), a lower risk for cardiovascular mortality was found for metformin monotherapy versus sulfonylurea monotherapy.
In the RCTs, the hazard ratios comparing sulfonylureas to all treatments combined were 1.26 (95% confidence interval, 1.10-1.44) for all-cause mortality and 1.46 (95% CI, 1.21-1.77) for cardiovascular (CV) mortality.
Metformin, which does not stimulate insulin, is still the cornerstone of initial therapy but sulfonylureas are losing their utility and popularity.
Rakesh Sahay highlighted the efficacy of combination of Sulfonylurea's and Metformin.